Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir.

Background: There is scant data on young children receiving protease inhibitor-based therapy in real-life resource-limited settings and on the optimal timing of therapy among children who survive infancy. Our aim was to evaluate outcomes at the Hospital del Niño, Panama, where children have been routinely treated with lopinavir/ritonavir (LPV/r)-based therapy since 2002.

Methods: Retrospective cohort analysis of all HIV-infected children enrolled in care between January 1, 1991, and June 1, 2011.